Theralase Technologies Inc. V.TLT

RE:RE:RE:RE:RE:RE:Lumeda News

[99942Apophis]

Rumpl3StiltSkin wrote

Eoganacht wrote: That's tough to say. Roswell Park has been sitting on their first IO-PDT NSCLC phase 1 trial (NCT03678350) for a long time. They first posted it on clinicaltrials.gov over 2 1/2 years ago and as of April 1, they are still listed as "Not yet recruiting" But it does look like they intend to start both phase 1 trials in 2021. But as we know, the pandemic isn't  helping any with patient recruitment, so who knows.

Roswell Park started investigating Dr. Mcfarland's compounds in 2019 and as the 2020 study shows they are seriously considering TLD1433 for their IO-PDT treatment. The question is, will they judge that the advantages of TLD1433 over photofrin in terms of being able to apply it topically and not having to worry about light sensitivity, overcome the disadvantages of having to make a deal with Theralase and use a (so-far) unapproved PDC that they did not create and improve themselves..

Back in 2016 Roswell Park successfully treated an early stage NSCLC patient using photofrin IO-PDT. Five years later they have still not started the phase 1 trial.

https://www.roswellpark.org/cancertalk/201702/lung-cancer-patient-helps-blaze-trail-possible-new-treatment-approach

Oilminerdeluxe wrote: So let's say it is indeed our magic ooze that will be used, realistically, how long should it take before any real data of worth is given us? I mean, everything always takes longer than one thinks or wants. An actual vaccine would be awesome of course, but the time aspect? On the other hand, it is TLT, we are used to waiting. A $-sign would be nice to see after all these years. Go TLT!
 

 

TLT might come up with their own delivery for NSCLC, that is the risk RPCC has if they don't lock up 1433 to use with the Lumeda device. With any monies $$ that TLT might get with Accelerated Approval for NMIBC, or an approved Covid 19 treatment/Vaccine, TLT should be able to go it alone.


I would like to add that watching Theralase form a collaboration in the Covid-19 vaccine might be the path that TLT will also take with RPCCC or partnership that will be announced at the start of their trial. To say this is getting exciting is definitely an understatement. My opinion is partnership covers more ground and opens other indications to be conquered.